Novartis adjusts production in Switzerland, 550 jobs lost
Keystone-SDA
Novartis is to end tablet and capsule production at its Stein site near Basel, in northern Switzerland, by 2027, cutting around 550 permanent jobs.
+ Get the most important news from Switzerland in your inbox
The site will be automated and remain a hub for sterile dosage forms and the commercial production of complex, personalised cell therapies, Novartis said in a statement on Tuesday. The company plans to invest $26 million (CHF21 million) to make this happen.
Novartis has started a consultation process, and affected staff will be covered by a social plan extended until 2028. The company says it will offer measures such as early retirement.
At the same time, Novartis plans to invest $80 million in its Schweizerhalle site, creating around 80 new full-time jobs by the end of 2028. The investment will support the development of siRNA, a key part of the group’s strategy for tackling cardiovascular, kidney and metabolic diseases.
Translated from French with DeepL/sp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
